Oral semaglutide (Rybelsus, Novo Nordisk) lowered hemoglobin A1c more than empagliflozin (Jardiance, Boehringer Ingelheim/Lilly) in a recently published open-label, head-to-head comparison of the type ...

A groundbreaking development in diabetes treatment reveals that SGLT-2 inhibitors significantly reduce dementia risk among type 2 diabetes patients. Recent research demonstrates these medications ...

Among diabetes drugs, GLP-1 receptor agonists and SGLT2 inhibitors were associated with greater reduction in the risk for Alzheimer’s disease (AD) than DPP-4 inhibitors, new research showed. “GLP-1 ...

The landscape of diabetes management is undergoing a remarkable transformation. Groundbreaking research has uncovered surprising cardiovascular benefits tied to modern medications, offering new hope ...

A large McGill University study has found that two classes of medications commonly prescribed for type 2 diabetes, both incretin-based, are associated with a reduced risk of dementia. Drawing on ...

Patterns differ among medication classes; potential mechanisms need more research ...

Add Yahoo as a preferred source to see more of our stories on Google. According to the WHO, more than 800 million people around the world have diabetes, with more than half of them not receiving ...

(HealthDay)—No single drug to treat type 2 diabetes stands out from the pack when it comes to reducing the risks of heart disease, stroke or premature death, a new research review finds. The analysis ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Most people ...